BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32162714)

  • 1. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
    Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
    Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
    Kim S; Li L; Zhang J; Jiang C; Lü J
    Prostate; 2022 Jan; 82(1):154-166. PubMed ID: 34662447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
    Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
    Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
    Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
    Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer.
    Wang C; Feng Y; Zhang C; Cheng D; Wu R; Yang Y; Sargsyan D; Kumar D; Kong AN
    FASEB J; 2020 Jan; 34(1):1304-1318. PubMed ID: 31914691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN-knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid.
    Wang L; Wang C; Sarwar MS; Chou P; Wang Y; Su X; Kong AT
    FASEB J; 2022 Nov; 36(11):e22626. PubMed ID: 36305462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
    Liao CP; Lin TP; Li PC; Geary LA; Chen K; Vaikari VP; Wu JB; Lin CH; Gross ME; Shih JC
    Oncogene; 2018 Sep; 37(38):5175-5190. PubMed ID: 29844571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
    Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
    Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice.
    Takahara K; Ibuki N; Ghaffari M; Tearle H; Ong CJ; Azuma H; Gleave ME; Pollak M; Cox ME
    Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):239-47. PubMed ID: 23689346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
    Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
    J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM
    Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate.
    Desai KV; Michalowska AM; Kondaiah P; Ward JM; Shih JH; Green JE
    Mol Endocrinol; 2004 Dec; 18(12):2895-907. PubMed ID: 15358834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
    Redmer T; Raigel M; Sternberg C; Ziegler R; Probst C; Lindner D; Aufinger A; Limberger T; Trachtova K; Kodajova P; Högler S; Schlederer M; Stoiber S; Oberhuber M; Bolis M; Neubauer HA; Miranda S; Tomberger M; Harbusch NS; Garces de Los Fayos Alonso I; Sternberg F; Moriggl R; Theurillat JP; Tichy B; Bystry V; Persson JL; Mathas S; Aberger F; Strobl B; Pospisilova S; Merkel O; Egger G; Lagger S; Kenner L
    Mol Cancer; 2024 May; 23(1):114. PubMed ID: 38811984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
    Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
    Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
    Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.
    Korsten H; Ziel-van der Made AC; van Weerden WM; van der Kwast T; Trapman J; Van Duijn PW
    PLoS One; 2016; 11(1):e0147500. PubMed ID: 26807730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.